Aytu BioPharma, Inc.

NasdaqCM:AYTU Stok Raporu

Piyasa değeri: US$11.9m

Aytu BioPharma Yönetim

Yönetim kriter kontrolleri 2/4

Aytu BioPharma's CEO is Josh Disbrow, appointed in Apr 2015, has a tenure of 9.58 years. total yearly compensation is $928.22K, comprised of 63.6% salary and 36.4% bonuses, including company stock and options. directly owns 1.17% of the company’s shares, worth $138.93K. The average tenure of the management team and the board of directors is 2.8 years and 8.3 years respectively.

Anahtar bilgiler

Josh Disbrow

İcra Kurulu Başkanı

US$928.2k

Toplam tazminat

CEO maaş yüzdesi63.6%
CEO görev süresi9.6yrs
CEO sahipliği1.2%
Yönetim ortalama görev süresi2.8yrs
Yönetim Kurulu ortalama görev süresi8.3yrs

Son yönetim güncellemeleri

It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Jun 20
It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Recent updates

Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly?

Nov 01
Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly?

It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Jun 20
It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year

Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden

Jun 14
Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden

US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Feb 17
US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Feb 16
Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

Jan 23
Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too

Sep 29
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too

Aytu stock falls amid suspending clinical programs to save costs

Oct 13

Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M

Sep 27

Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder

Sep 14

Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders

Aug 16

Aytu BioPharma plunges on pricing $10M stock and warrants offering

Aug 09

Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00

May 19
Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00

Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?

Sep 11
Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?

Aytu BioPharma up 21% in afternoon trading

Jun 21

Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now

May 15
Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now

A Quick Analysis On Aytu BioScience's (NASDAQ:AYTU) CEO Compensation

Feb 14
A Quick Analysis On Aytu BioScience's (NASDAQ:AYTU) CEO Compensation

CEO Tazminat Analizi

Josh Disbrow'un ücretlendirmesi Aytu BioPharma'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024US$928kUS$590k

-US$16m

Mar 31 2024n/an/a

-US$14m

Dec 31 2023n/an/a

-US$18m

Sep 30 2023n/an/a

-US$24m

Jun 30 2023US$708kUS$590k

-US$17m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022n/an/a

-US$77m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022US$590kUS$590k

-US$109m

Mar 31 2022n/an/a

-US$112m

Dec 31 2021n/an/a

-US$84m

Sep 30 2021n/an/a

-US$82m

Jun 30 2021US$6mUS$545k

-US$58m

Mar 31 2021n/an/a

-US$42m

Dec 31 2020n/an/a

-US$22m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020US$2mUS$608k

-US$14m

Mar 31 2020n/an/a

-US$25m

Dec 31 2019n/an/a

-US$24m

Sep 30 2019n/an/a

-US$29m

Jun 30 2019US$1mUS$330k

-US$27m

Mar 31 2019n/an/a

-US$12m

Dec 31 2018n/an/a

-US$10m

Sep 30 2018n/an/a

-US$9m

Jun 30 2018US$606kUS$303k

-US$10m

Tazminat ve Piyasa: Josh's total compensation ($USD928.22K) is above average for companies of similar size in the US market ($USD655.65K).

Tazminat ve Kazançlar: Josh's compensation has increased whilst the company is unprofitable.

CEO

Josh Disbrow (49 yo)

9.6yrs

Görev süresi

US$928,217

Tazminat

Mr. Joshua R. Disbrow, also known as Josh, serves as Chairman at Aytu Biopharma, Inc. He served as Chairman at Aytu Biopharma, Inc. (formerly known as Aytu BioScience, Inc.) since July 2016 until 2023 and...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Joshua Disbrow
Chairman & CEO9.6yrsUS$928.22k1.17%
$ 138.9k
Mark Oki
CFO, Secretary & Treasurer2.8yrsUS$584.67k0.15%
$ 18.4k
Jarrett Disbrow
Chief Business Officer2yrsUS$542.10k0.21%
$ 24.8k
Greg Pyszczymuka
Chief Commercial Officer2.8yrsUS$516.30k0.38%
$ 44.9k
Margaret Cabano
Vice President of Operationsno dataVeri yokVeri yok
Russ McMahen
Senior Vice President of Research & Developmentno dataVeri yokVeri yok
Ryan Selhorn
Executive Vice President of Finance & Business Optimization2yrsVeri yokVeri yok

2.8yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim: AYTU's management team is considered experienced (2.8 years average tenure).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Joshua Disbrow
Chairman & CEO8.8yrsUS$928.22k1.17%
$ 138.9k
Vivian Liu
Independent Director2.3yrsUS$77.60k0.14%
$ 16.1k
John Donofrio
Lead Independent Director8.3yrsUS$107.60k0.037%
$ 4.4k
Carl Dockery
Independent Director8.6yrsUS$72.60k0.16%
$ 18.7k
Abhinav Jain
Independent Director1.4yrsUS$79.30k0.13%
$ 15.5k

8.3yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AYTU's board of directors are considered experienced (8.3 years average tenure).